Acacia Pharma Group plc

Jefferies London Healthcare Conference Presentation
November 2021

Delivering innovative products to
enhance surgical patients' recovery

acacia pharma

Important Notice

The information contained in this presentation (this **"presentation"**) has been prepared by Acacia Pharma Group plc ("the **Company**") as at the date of this presentation and is subject to updating, completion, revision, further verification and amendment without notice. This presentation is for general information only and is the property of the Company. Making this presentation available in no circumstances whatsoever implies the existence of a commitment or contract by or with the Company, or any of its affiliated entities, or any of its or their respective subsidiaries, directors, officers, representatives, employees, advisers or agents for any purpose.

This presentation has not been approved by the United Kingdom Listing Authority under the Prospectus Rules (made under Part VI of the Financial Services and Markets Act 2000 ("**FSMA**")), by the Belgian Financial Services and Markets Authority or otherwise, by the regulated market of Euronext Brussels. This presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this presentation or on the completeness, accuracy or fairness thereof.

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company or its directors, officers, partners, employees, agents or advisers or any other person as to the accuracy or completeness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any of them for any such information or opinions or for any errors, omissions, misstatements, negligence or otherwise for any other communication written or otherwise. In addition, in issuing this presentation, the Company undertakes no obligation to update or to correct any inaccuracies which may become apparent in this presentation. Notwithstanding the aforesaid, nothing in this paragraph shall exclude liability for any undertaking, representation, warranty or other assurance made fraudulently.

The statements contained in this presentation may include "forward looking statements" that express expectations of future events or results. All statements based on future expectations rather than on historical facts are forward looking statements that involve a number of risks and uncertainties and the Company cannot give assurance that such statements will prove to be correct. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. The Company gives no undertaking to update forward looking statements to reflect any changes in expectations, events, conditions or circumstances upon which such statements are made.

The presentation should not be considered a recommendation by the Company or any of its affiliated entities, or any of its or their respective subsidiaries, directors, officers, representatives, employees, advisers or agents in connection with any purchase of or subscription for securities of the Company.

This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. In particular, this presentation should not be copied or distributed by recipients and should not be distributed by any means including electronic transmission, to persons with addresses in the United States of America, Canada, Australia, South Africa or Japan their possessions or territories or to any citizens thereof, or to any corporation, partnership or such entity created or organised under the laws thereof. Any such distribution contrary to the above could result in a violation of the laws of such countries.

acacia pharma

Acacia Pharma Group – Overview

BARHEMSYS® – FDA approved for PONV, launched late 2020

- Broad label for prevention and treatment of Post-Operative Nausea and Vomiting (PONV)
- Only agent approved for 'Rescue' of ~16m patients p.a. in US with PONV after generic antiemetics fail[1]
- PONV "rescue" is an estimated $2.7 billion annual total addressable market[2]

BYFAVO® – In-licensed, FDA approved for procedural sedation, launched Jan 2021

- Indicated for procedural sedation in adults – launch benefitting from shared value proposition
- Key target: 40m procedures a year in US, including 25m GI procedures[3]
- Estimated >$1.5 billion annual total addressable market[4]

Commercialization and engagement with KOLs showing good progress

- Strong, experienced team has effectively engaged with customers both virtually and live when possible
- Customers have provided very positive feedback on their initial experiences with the products
- Initiated the Byfavo pediatric study and have seen significant KOL interest in further studying Byfavo
- Partnering with key institutions to begin the Barhemsys PROMPT study to gather real-world evidence

1 Calculations based on available procedural data, applied Compound Annual Growth Rate and quantitative market research responses as follows: National Hospital Discharge Survey, 2006; National Survey of Ambulatory Surgery, 2006 (as revised in 2009); Source Healthcare; NCHS 2005; Life Science Strategy Group, LLC Market Research; Apfel et al.,2004. 2 Based on the calculations in (1) multiplied by the number of doses per patient at a WAC price of $85 per 10mg dose. 3 iData Research, US Market Report Procedure Numbers for Gastrointestinal Endoscopic Devices February 2019; American Society of Anesthesiologists, Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018; and Quantitative Market Research prepared by The Link Group for Cosmo Technologies (March 2019). 4 Based on the calculation in (4) multiplied by the number of doses per patient at a WAC price of $39 per dose.

acacia pharma

Leadership Team with Experience to Deliver the Vision

Mike Bolinder
CEO

- Joined 2015, became CEO 1 August 2019
- 20 years experience in life sciences
- Relevant commercial experience with OFIRMEV® at Cadence/Mallinckrodt

Gary Gemignani
CFO

- Joined as CFO January 2020
- 30+ years finance experience in healthcare
- Relevant CFO experience in early commercial stage pharma

Deb Hussain
CCO

- Joined as CCO May 2021
- 20+ years in pharma sales & marketing
- Relevant commercial launch experience with multiple pharma brands

Dr Gabriel Fox
CMO

- Joined as CMO 2008
- 24 years in pharmaceutical medicine
- Relevant development and medical-marketing experience in repurposed drugs

acacia pharma

We have been able to make significant progress in a very challenging operational environment caused by the global pandemic

> The OR accounts for up to 65% of hospital profit margin, so this missing volume is cutting deeply into cash flow and net income.
>
> – Becker's Hospital Review[1]

COVID-19 impact on hospitals and surgical centers	• Non-essential surgeries cancelled creating a significant backlog • Physical access to hospital decision-makers even more restricted
Hospital profits have suffered and need to be restored quickly	• Surgeries and procedures are major contributors to hospital profits • Providers need to dramatically increase throughput to regain lost profits
We believe our products and team are ideally positioned to help	• BARHEMSYS and BYFAVO can help improve patient throughput – both are now even more relevant and of greater interest to customers due to COVID • Our strong relationships are helping us gain access to key decision-makers

1 How to rebuild surgical revenue after COVID-19, **Becker's Hospital Review**, accessed via https://www.beckershospitalreview.com/strategy/how-to-rebuild-surgical-revenue-after-covid-19-even-if-you-just-lost-60-of-your-or-volume.html

acacia pharma

BARHEMSYS®

(amisulpride for injection)

The first and only FDA-approved product for PONV rescue treatment[1]

1 FDA labels for other recommended treatments do not include treatment after failed prophylaxis. Treatment agents recommended by Society for Ambulatory Anesthesiology Consensus Guidelines (2014). Habib et al (2019): no agent has previously been shown in a prospective trial to be more effective than a placebo for treating PONV for patients who have failed prophylaxis.

acacia pharma

BARHEMSYS® and the PONV Commercial Opportunity

BARHEMSYS Addresses the major unmet need in PONV

- BARHEMSYS is the **only FDA-approved drug for PONV rescue** after failed prophylaxis[1]
- Dopamine D_2/D_3 antagonist with **broad, differentiated label**
- Offers significant **economic savings** to hospital vs current standard of care

Large but concentrated US market opportunity in PONV[2]

- Estimated ~65m eligible surgeries annually, ~49m patients receive preventative antiemetics[3]
- **Total addressable PONV rescue market estimated at ~$2.7 billion/year[4]**
- Estimated 80% of surgeries carried out in ~1,200 hospitals[5]

High gross profit, secure supply chain and worldwide rights

- **Cost of goods ~10% of sale price**
- Substantial product inventory to minimize supply risk
- **Worldwide rights and exploring out-licensing opportunities in OUS markets**

Can help with COVID surgical backlogs

- "The OR accounts for up to 65% of hospital profit margin" – Becker's Hospital Review[6]
- Non-essential surgery cancellations create significant backlogs
- **Shorter time in PACU (recovery room) can help increase surgical throughput**

1 FDA labels for other recommended treatments do not include treatment after failed prophylaxis, 2 This is the belief of the Company. 3 Company market size estimates based upon: 2006 National Hospital Discharge Survey; National Survey of Ambulatory Surgery, 2006 (as revised in 2009); LSSG Quantitative Research November 2014; Apfel, NEJM 2004. Calculations based on available procedural data, applied Compound Annual Growth Rate and quantitative market research responses. 4 Based upon WAC price of $85 per 10mg rescue dose with, on average, 2 rescue doses per patient, and the above estimates. 5 Symphony Health, Source Non Retail, August 2017 - July 2018. estimates
6 How to rebuild surgical revenue after COVID-19, **Becker's Hospital Review**, accessed via https://www.beckershospitalreview.com/strategy/how-to-rebuild-surgical-revenue-after-covid-19-even-if-you-just-lost-60-of-your-or-volume.html

acacia pharma

Nausea and Vomiting is a Complex Process

Managed by combinations of antiemetics targeting multiple mechanisms



Multiple pathways, including:
- Serotonin (5-HT_3)
- **Dopamine (D_2)**
- Histamine
- NK1

Current standard of care for PONV prophylaxis[1]:
5-HT_3 antagonist
(e.g. ondansetron)
± corticosteroid

Despite this >30% of surgical patients still get PONV[2]

1 Gan et al, 2020. 2 Apfel et al, 2004; Habib et al, 2019.

acacia pharma

Targeting PONV Rescue Market



Total estimated addressable market in PONV rescue ≈ $2.7B per year

Secondary market in combination prophylaxis in highest-risk patients, estimated to be worth $765M per year[2]

1 Company market size estimates based upon: 2006 National Hospital Discharge Survey; National Survey of Ambulatory Surgery, 2006 (as revised in 2009); LSSG Quantitative Research November 2014; Apfel et al, 2004. Calculations based on available procedural data, applied Compound Annual Growth Rate and quantitative market research responses. 2 Based on WAC price of $85 per 10 mg rescue dose and average 2 rescue doses per patient; $42.50 per 5 mg prophylaxis dose.

acacia pharma

BARHEMSYS® is the Only FDA-Approved Product for PONV Rescue

> When PONV prophylaxis has failed, patients should receive antiemetic treatment from a different pharmacological class to the PONV prophylaxis
>
> – Consensus Guidelines[1]

Antiemetic	Can't redose	Efficacy issues	Safety issues	Current share of rescue patients[4]
Ondansetron	✗[1]			69%
Dexamethasone	✗[1]	✗[2]		19%
Metoclopramide		✗[1]	✗[1]	19%
Promethazine			✗[1]	11%
BARHEMSYS	✓[3]	✓[3]	✓[3]	**INTENT TO PRESCRIBE**[4] 61%

1 Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. 2 Wang et al (2000). 3 BARHEMSYS label prescribing information. 4 LSSG quantitative market research among 152 anesthesiologists and general surgeons. Question referred to "Product X" with a description matching the profile of BARHEMSYS. Note: current shares totals > 100% as responses included some combination therapy.

acacia pharma

Barhemsys – Compelling Commercial Proposition

Significant unmet need

- Nausea more so than vomiting, worse than pain
- Consensus Guidelines: "When PONV prophylaxis has failed, patients should receive antiemetic treatment from a different pharmacological class to the PONV prophylaxis"[1]

Only FDA-approved product for PONV rescue[2]

- Only drug proven in randomized clinical trial to work in PONV rescue[3]
- Excellent safety profile demonstrated in clinical studies
- Also demonstrated to be effective for prevention

Throughput and health economic benefits

- Is non-sedating – a common complaint of standard antiemetic agents
- 35-minute reduction in PACU stay, 6-hour reduction in hospital stay
- Offers significant economic savings to hospital vs current standard of care

1 Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting; 2 FDA labels for other recommended treatments do not include treatment after failed prophylaxis. Treatment agents recommended by Society for Ambulatory Anesthesiology Consensus Guidelines (2014). Habib et al (2019): no agent has previously been shown in a prospective trial to be more effective than a placebo for treating PONV for patients who have failed prophylaxis. 3 FDA labels for other recommended treatments do not include treatment after failed prophylaxis.

acacia pharma

Highly Experienced Commercial Team is Driving Formulary Adoption



Commercial Leadership Team has 28+ years average in the industry and experience with 70+ launches

Field Force Design

- 1 SVP of Field Commercial Teams
- 1 National Accounts Group Leader
- 1 National MSL Group Leader
- 6 Sales Regions including:
  - Regional Brand Directors
  - Medical Science Liaisons
  - National Account Directors
  - Hospital Territory Managers

Sales Leadership Team

22	19+
Years avg Industry	Years Hospital

Hospital Territory Managers

22+	13+
Years avg Industry	Years Hospital

National Accounts Team

25	23+
Years avg Industry	Years Hospital

Medical Science Liaison Team

22	10+
Years avg Industry	Years as MSL

acacia pharma

Barhemsys – Comprehensive Customer Engagement Plan







- Full 2021 Medical congress plan
  - Regional/state congresses: 24
- Peer-to-peer programs: 150+ live and virtual programs
- Digital brand engagements in the most trusted anesthesia publications with 89% readership (51K members)
  - Special report distributed to all Anesthesia targets October ‘21
- Robust digital and print media plan under way across Anesthesia, Pharmacy and Surgery
- All promotional materials available both physically and digitally

acacia pharma

Hospital Launch: Strategic Focus on Formulary Reviews & Adoption



Formulary Review Process

- Identify “champions” within each facility
- Educate and prepare “champions” for P&T Committee
- Highlight current unmet needs with existing products
- Educate on efficacy and safety data for our products
- Barhemsys and Byfavo can provide economic savings to hospital vs current standard of care

Pull-Through Process

- Ensure our brands are within the workflow of the healthcare providers
- Conduct in-service presentations to educate nurses and staff

acacia pharma

BYFAVO®

(remimazolam) for injection

Rapid onset/offset procedural sedative with favorable safety profile

acacia pharma

Procedural Sedation Market Opportunity

~40 million[1]

procedures each year requiring sedation

~25 million

GI procedures performed each year[2]

>80%

GI procedures have sedation administered by an anesthesia provider[3]



>6 million

Interventional Radiology[4]



~4 million

Ophthalmic Procedures[5]

~1 million

Bronchoscopy[6]

~1.5 million

Cosmetic/ Plastic Surgery[7]

Total addressable market in procedural sedation >$1.5B/year[8]

1 Calculations based on available procedural data, applied Compound Annual Growth Rate and quantitative market research responses. 40 million includes other opportunities: CC (MHA National) EP (dicardiology), Dental (areadentist), Plastic Surgery (American Society of Plastic Surgeons), ECT (MHA National). 2 iData Research, US Market Report Procedure Numbers for Gastrointestinal Endoscopies Nov 2016; CDC website. 3 Quantitative Market Research prepared by The Link Group for Cosmo Technologies (March 2019). 4 Report on interventional Radiology November/December 2007. 5 American Medical Association 2011. 6 iData Bronchoscopy 2019 report. 7 American Society of Plastic Surgeons 2018. 8 Based on the calculation in iData Research, US Market Report Procedure Numbers for Gastrointestinal Endoscopic Devices February 2019; American Society of Anesthesiologists, Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018; and Quantitative Market Research prepared by The Link Group for Cosmo Technologies (March 2019) multiplied by the number of doses per patient at a WAC price of $39 per dose.

acacia pharma

BYFAVO Addresses Unmet Need in Procedural Sedation

Propofol

fast acting but significant safety issues[1,2]

- Rapid onset and offset anesthetic with narrow therapeutic index[1]
- **Dose-related cardiorespiratory depression**, pain at injection site[1]
- Non-linear dosing effects due to individual variability[4]
- **Needs continuous monitoring by anesthesiologist, no reversal agent[2]**
- Lipid formulation susceptible to bacterial contamination[4]

Midazolam

better safety profile but longer onset and recovery[1,2]

- Benzodiazepine sedative, reversible by flumazenil[1]
- **Slower onset and offset[2,3]**
- Metabolized by cytochrome system; individual variability affects sedation[1]
- Active metabolite can accumulate and cause prolonged sedation[2]
- **Risk of respiratory depression[1]**

BYFAVO

fast acting AND favorable safety profile[1,2]

- **Rapid onset/offset[1,2,3]** benzodiazepine
- Rapid biotransformation into inactive metabolites via non-specific tissue esterases – not dependent on liver enzymes[1]
- **Predictable behavior, no pharmacokinetic drug interactions[5]**
- **Reliable sedation, reliable safety profile[1]**
- Reversible by flumazenil[1]

1 Colao J, et al. *J Anesth Clin Res*. 2016; 7:690. 2 Whizar-Lugo V, et al. *J Anesth Crit Care*. 2016; 4(6): 00166. 3 Rex DK et al. Gastrointest Endosc. 2018 Sep;88(3):427-437.
4 Prescribing label for Propofol. 5 Prescribing label for BYFAVO.

acacia pharma

Rapid Onset/Offset with a Favorable Safety Profile[1]

Average Procedure Timings[1]



Key Adverse Events[1]

	BYFAVO	Midazolam
Any adverse event	**74%**	**91%**
Vascular disorders	62%	81%
Cardiac disorders	18%	26%
Respiratory disorders	4%	6%

1 Rex DK et al. Gastrointest Endosc. 2018 Sep;88(3):427-437.

acacia pharma

Byfavo – Compelling Commercial Proposition

Clear unmet need

- No innovation in the sedation space for 20+ years
- Customers seeking fast onset, titratable, & rapid recovery for quick discharge
- Shorter procedure times allow increased procedural volumes

Broad label & health economic benefits

- Indicated for procedural sedation in adults in procedures lasting 30 mins or less
- Substantial clinical data package shows compelling efficacy and safety in colonoscopies and bronchoscopies, including most challenging patients
- Enables shorter procedure times and greater patient throughput

Commercial synergy with Barhemsys

- Target prescribers: anesthesia providers and proceduralists in hospitals and ambulatory surgery centers

acacia pharma

Byfavo - Launching the First New Sedative in the US for 20 years

- Full congress plan across Anesthesia, Pharmacy, including key GI and Pulmonology
  - Regional/state congresses: 24
- On demand virtual and live promotional programming, featuring anesthesia, GI, and pulmonary investigators and trained speakers
- Robust digital and print media plan under way across Anesthesia, GI, Pharmacy and Surgery/proceduralists
- All promotional materials available in both digital and physical format

acacia pharma

Commercial Progress as of 30 September 2021

260 accounts on formulary
[Goal: 300]
>80% win rate
[Goal: 75%]

>185 accounts have ordered Barhemsys

73% of ordering accounts with Barhemsys on formulary have placed repeat orders







95 accounts on formulary
[Goal: 150]
>90% win rate
[Goal: 75%]

>50 accounts have ordered Byfavo

81% of ordering accounts with Byfavo on formulary have placed repeat orders

acacia pharma

Financials

acacia pharma

Acacia Pharma Group – Financial Summary

Listed on Euronext Brussels exchange

- IPO in March 2018
- ~99.7m shares outstanding
- ~80% free float

Cash position

- Cash and cash equivalents as of 30 June 2021 was $47.1m
- Equity financing in February 2021 with gross proceeds of €27m (~$33m)

Debt

- Early repayment of Hercules debt in May 2021
- Cosmo ~€25m outstanding loan

acacia pharma

Summary

acacia pharma

In Summary

Our products address **unmet medical needs** in therapeutic areas with **large total addressable market opportunities** (~$2.7B in PONV rescue, >$1.5B in procedural sedation)

The team continues to make **tremendous progress in 2021** despite a very challenging operating environment due to the global pandemic

We continue to see a **great response from customers at launch adding our products to formulary** with continued positive customer feedback on both products

We believe we have **the right team, with the right experience** and have set the stage for significant commercial success in the years to come

Q&A

acacia pharma